ACM
AMPH icon

Aster Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Aster Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$5.36K – 836
2025
Q4 		$5.36K Buy
+200
New +$5.15K ﹤0.01% 859
2025
Q1 		– Sell
-2,869
Closed -$107K – 1233
2024
Q4 		$107K Buy
+2,869
New +$131K 0.04% 375

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Aster Capital Management's AMPH Position: Q1 2026 in Review

Aster Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 200 shares — an estimated $5.36K sold.

Aster Capital Management first reported a position in AMPH in Q4 2024 and held it in 2 quarters. The position peaked at $107K in Q4 2024. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Aster Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 200 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $5.36K.
  • Aster Capital Management first reported a position in Amphastar Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Aster Capital Management's Amphastar Pharmaceuticals position peaked at $107K in Q4 2024.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.